Reason for request
Inclusion
No clinical benefit demonstrated in dual therapy with metformin or in triple therapy with metformin/sulfonylurea or metformin/insulin in the management of type 2 diabetic patients inadequately controlled with metformin, or with a combination of metformin and a sulfonylurea or metformin and insulin
No clinical benefit in monotherapy or in dual therapy with a sulfonylurea or insulin
- JARDIANCE has Marketing Authorisation in the treatment of type 2 diabetes in monotherapy and in combination with other blood glucose-lowering medicinal products, including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- The available clinical data are based mainly on studies versus placebo, whereas active comparators do exist. Just one study has shown modest efficacy for JARDIANCE 25 mg/day versus glimepiride (sulfonylurea) 1-4 mg/day whereas its maximum dose is 6 mg/day.
Clinical Benefit
| Moderate |
Monotherapy : Insufficient for reimbursement by National Health Insurance
Dual therapy :
- with metformin : Moderate
Tritherapy :
- with metformin and a sulfonylurea : Moderate
- with insulin and metformin : Moderate |
| Insufficient |
- with a sulfonylurea : Insufficient for reimbursement by National Health Insurance
- with insulin : Insufficient for reimbursement by National Health Insurance |
Clinical Added Value
| no clinical added value |
In the indications as dual therapy with metformin, and as tritherapy with metformin and a sulfonylurea or with metformin and insulin :
In light of the available clinical data, namely placebo-controlled studies with empagliflozin 10 or 25 mg/day when active comparators are available and modest
results from a sequential non-inferiority and superiority study of empagliflozin at its maximum dose of 25 mg/day versus an active comparator, the sulfonylurea glimepiride, at doses of 1 to 4 mg/day (whereas its maximum dose is 6 mg/day), the Committee considers that the JARDIANCE proprietary medicinal products do not provide any improvement in actual benefit (level V, non-existent) in the management of patients with poorly controlled type 2 diabetes, as dual oral therapy in combination with metformin and as tritherapy in combination with metformin and a sulfonylurea or with metformin and insulin.
In the indications as monotherapy, and as dual therapy with sulfonylureas or insulin : Not applicable. |
| Not applicable |
|
eNq1mFFv2jAQx9/5FFHeSUhbOpgC1cbaDanVGC3atJfKJEdxltrp2Qa6Tz+H0BUmRx0GP8Z2/nf2nX93cnyxesy9BaCgnPX8KGj5HrCEp5Q99PzJ3VWz41/0G3FGFuR12YleF0SR7yU5EaLnl7PBFAgTwY+b60+g/wf0+w0v5tMMErmzTkmaB1+ImN+QolzjxQtOU+8R5JynPb9Qcj3qxUKi9qK/5PhLFCSBONyMbM9m92fb43FYiv2HqhKA14Q9GEWBWWkmChGYHBAJDxyfa/w9tdKmYgyCK0xgROR8hHxBU0iNJmYkF2BlZLZMbwEXOcjSiFE8zJJHYSVOMrIaw9PQ7PQHPTuQK9lsNaN33ei8fdZpRZ1u18oUbh2VOQp6E2Fyf9JqnXbapyGwMCOYUsISsIzOiKMkuaO4UDHYTS1HdhCe3ox/SkWRk+cgE4XtUREkehpQA8DdRsod3KFGUq7P7B99pvI83NPryQYYjjwueTTgiskablyNbQ9iwJmEVX1E7VAnV5tcpCCOJ/ubMzPmR2qa08QWaho7CoScjIf1TDsuDj4SARN0x4PvlKV8KY7Pme24OvK+WKPSKFpgGt2fdDvnUbttfY1+6iSqqTKXCnkBoSYQFYeAZchm/FCk6Lw0S71k5RETct3t8ITkUNPvNC35ojPxpT1zluvu7lE1YRT9fHlnmyDfFODz7frTKE3T3t/Q2sHXBdF1OtY6vn9yV3fcSSes0MyOuZSFeB+Gy+UymBPRFESfUjBDB3TfKqnuOnEndbvqYypCOnJ9WpW+/WJke9fequyHdqub/zddsdGGRAUHxKLCsjN4Di+Pz+PXVtWZ26Mdfrgzs24riaScuWp21NSoeFgF0HFlV6gB8XU2ozUvI7V5GYfVq0y/EYfli0y/8QdEPedW
bSHQRYyeQndGqW9R
